Patents by Inventor Adrian V. S. Hill
Adrian V. S. Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11306325Abstract: The present invention provides recombinant adenoviral vectors, immunogenic compositions thereof and their uses in medicine. In particular, the present invention provides an adenoviral vector comprising the genome of an adenovirus other than AdHu5 and AdY25, wherein the genome of the adenovirus has been modified such that the vector lacks the native E4 locus of the adenovirus and comprises heterologous E4Orf1, E4Orf2 and E4Orf3 coding regions from AdY25.Type: GrantFiled: June 23, 2017Date of Patent: April 19, 2022Assignee: Oxford University Innovation LimitedInventors: Sarah C. Gilbert, Adrian V S Hill, Matthew G. Cottingham, Matthew Dicks, Susan J. Morris, Alexander Douglas
-
Publication number: 20220001007Abstract: The invention relates to a viral vector comprising nucleic acid having a polynucleotide sequence encoding at least one epitope of the varicella-zoster virus (VZV) Gly E antigen, wherein said viral vector is an adenoviral vector. The invention also relates to uses, compositions for use in medical treatments, and methods of medical treatment.Type: ApplicationFiled: November 5, 2019Publication date: January 6, 2022Inventors: Sarah C. GILBERT, Sarah SEBASTIAN, Marta ULASZEWSKA, Adrian V.S. HILL, Teresa LAMBE
-
Patent number: 11065320Abstract: The invention relates to a kit comprising at least a first composition and a second composition, each said first and second compositions comprising at least one epitope of a liver disease antigen, wherein said epitope is a CD8+T cell epitope, for use in induction of an immune response in the liver of a mammalian subject by administration of said first composition by intramuscular (i.m.), subcutaneous (s.c.), intradermal (i.d.) or aerosol route, and administration of said second composition by intravenous (i.v.) or subcutaneous (s.c.) route, characterised in that said first and second compositions are administered by different routes. The invention also relates to uses, methods and treatments.Type: GrantFiled: April 11, 2017Date of Patent: July 20, 2021Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Adrian V. S. Hill, Anita Gola, Adam Walters, Alexandra Spencer
-
Publication number: 20200207811Abstract: The invention relates to a composition comprising a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID NO: 1, or a sequence having at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity to SEQ ID NO: 1 (R21), wherein said polypeptide is in the form of a virus-like particle (VLP), wherein said particle comprises less than 10% free hepatitis B surface antigen protein, for use in the immunisation of a human subject susceptible to Plasmodium falciparum infection, characterised in that said composition is administered in a dosage regimen of at least one dose of 1 ?g to 20 ?g R21 per administration for a subject at least 18 years old, or at least one dose of 0.5 ?g to 10 ?g R21 per administration for a subject less than 18 years old. The invention also relates to kits, methods and uses.Type: ApplicationFiled: July 27, 2018Publication date: July 2, 2020Inventors: Adrian V.S. HILL, Katie EWER
-
Publication number: 20190175714Abstract: The invention relates to a kit comprising at least a first composition and a second composition, each said first and second compositions comprising at least one epitope of a liver disease antigen, wherein said epitope is a CD8+T cell epitope, for use in induction of an immune response in the liver of a mammalian subject by administration of said first composition by intramuscular (i.m.), subcutaneous (s.c.), intradermal (i.d.) or aerosol route, and administration of said second composition by intravenous (i.v.) or subcutaneous (s.c.) route, characterised in that said first and second compositions are administered by different routes. The invention also relates to uses, methods and treatments.Type: ApplicationFiled: April 11, 2017Publication date: June 13, 2019Inventors: Adrian V. S. HILL, Anita GOLA, Adam WALTERS, Alexandra SPENCER
-
Patent number: 10286060Abstract: The invention relates to a composition suitable for inducing a T cell mediated immune response against an influenza virus in a vertebrate, said composition comprising nucleic acid encoding one or more epitopes of one or more internal proteins of influenza virus, wherein said composition comprises nucleic acid encoding at least two said epitopes, at least one epitope being from each of two or more internal proteins of influenza virus. The invention also relates to uses of same and to methods involving same.Type: GrantFiled: October 24, 2014Date of Patent: May 14, 2019Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Sarah Gilbert, Adrian V. S. Hill, Anne Moore
-
Publication number: 20150110831Abstract: The invention relates to a composition suitable for inducing a T cell mediated immune response against an influenza virus in a vertebrate, said composition comprising nucleic acid encoding one or more epitopes of one or more internal proteins of influenza virus, wherein said composition comprises nucleic acid encoding at least two said epitopes, at least one epitope being from each of two or more internal proteins of influenza virus. The invention also relates to uses of same and to methods involving same.Type: ApplicationFiled: October 24, 2014Publication date: April 23, 2015Inventors: Sarah Gilbert, Adrian V.S. Hill, Anne Moore
-
Patent number: 8734806Abstract: The invention relates to an immunogenic composition comprising an adenoviral vector and a pox viral vector, or two different adenoviral vectors, wherein one or more of the vectors encodes one or more target antigens; and related methods, uses and kits.Type: GrantFiled: December 23, 2009Date of Patent: May 27, 2014Assignee: ISIS Innovation LimitedInventors: Adrian V. S. Hill, Arturo Reyes-Sandoval
-
Publication number: 20130110078Abstract: The present invention provides vaccination methods using microneedle arrays which, when applied to the skin of a subject, create a defined total pore volume. Arrays may be chosen of varying total microneedle volumes (small, intermediate or large) for use in immunisation regimes to induce different T-cell and antibody responses in the subject. The present invention also provides kits for use in such vaccination method(s) comprising the appropriate microneedle array(s).Type: ApplicationFiled: April 28, 2011Publication date: May 2, 2013Inventors: Anne C. Moore, Frances Pearson, Adrian V.S. Hill, Abina M. Crean, Conor O'Mahony, Marie G. McGrath, John B. Carey
-
Publication number: 20120076818Abstract: The invention relates to an immunogenic composition comprising an adenoviral vector and a pox viral vector, or two different adenoviral vectors, wherein one or more of the vectors encodes one or more target antigens; and related methods, uses and kits.Type: ApplicationFiled: December 23, 2009Publication date: March 29, 2012Applicant: ISIS INNOVATION LIMITEDInventors: Adrian V. S. Hill, Arturo Reyes-Sandoval
-
Publication number: 20110159034Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: November 5, 2010Publication date: June 30, 2011Inventors: Andrew McMICHAEL, Adrian V.S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20100285050Abstract: The invention relates to a composition suitable for inducing a T cell mediated immune response against an influenza virus in a vertebrate, said composition comprising nucleic acid encoding one or more epitopes of one or more internal proteins of influenza virus, wherein said composition comprises nucleic acid encoding at least two said epitopes, at least one epitope being from each of two or more internal proteins of influenza virus. The invention also relates to uses of same and to methods involving same.Type: ApplicationFiled: September 29, 2008Publication date: November 11, 2010Applicant: Isis Innovation LimitedInventors: Sarah Gilbert, Adrian V.S. Hill, Anne Moore
-
Publication number: 20100119551Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: June 19, 2009Publication date: May 13, 2010Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20090324632Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: May 15, 2009Publication date: December 31, 2009Applicant: Oxxon Therapeutics Ltd.Inventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20090191237Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: August 4, 2008Publication date: July 30, 2009Applicant: Oxxon Therapeutics LimitedInventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Patent number: 7514087Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumor antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: GrantFiled: April 28, 2004Date of Patent: April 7, 2009Assignee: Oxxon Therapeutics LimitedInventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20080220000Abstract: This application relates to a method for generating an improved immune response in a host. The method involves the step of administering a vectored vaccine in the presence of an agent that impairs Treg cell function.Type: ApplicationFiled: May 3, 2005Publication date: September 11, 2008Inventors: Anne Clare Moore, Adrian V.S. Hill
-
Patent number: 7407661Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: GrantFiled: April 28, 2004Date of Patent: August 5, 2008Assignee: Oxxon Therapeutics LimitedInventors: Andrew McMichael, Adrian V. S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Patent number: 7273605Abstract: The present invention relates to a fowlpox virus genome which has modifications in one or more wild-type FPV genes. The present invention also relates to a viral particle comprising such a genome and its use to deliver a nucleotide of interest (NOI) to a target cell. The present invention also relates to vaccination methods, particularly a method which comprises administering a priming composition (which comprises a first non-replicating viral vector) and a boosting composition (which comprises a second non-replicating viral vector) to a subject to treat and/or prevent a disease.Type: GrantFiled: May 27, 2004Date of Patent: September 25, 2007Assignee: Isis Innovation LimitedInventors: Stephen Laidlaw, Mike Skinner, Adrian V. S. Hill, Sarah C. Gilbert, Richard Anderson
-
Publication number: 20040213799Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: October 16, 2003Publication date: October 28, 2004Applicant: Oxxon Pharmaccines LimitedInventors: Andrew McMichael, Adrian V.S. Hill, Sarah C. Gilbert, Jorg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard